SU11652 inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Guo, Yao ^a,b   Chen, Yun ^b   Xu, Xuesong ^a   Fu, Xueqi ^a   Zhao, Zhizhuang Joe ^a,b  

^a JILIN UNIVERSITY   (China)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; FLT3; Inhibitor screening; SU11652; Tyrosine kinase

Indexed keywords

CD135 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; STAT PROTEIN; SU 11652; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; INTRACELLULAR SIGNALING;

CELL GROWTH PROCESSES; CELL LINE, TUMOR; FMS-LIKE TYROSINE KINASE 3; HUMANS; INDOLES; LEUKEMIA, MYELOID, ACUTE; PROTEIN KINASE INHIBITORS; PYRROLES; SIGNAL TRANSDUCTION;

EID: 84870405511     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-72     Document Type: Article

References (26)

1. Acute myeloid leukaemia. Estey E, Döhner H, Lancet 2006 368 1894 1907 10.1016/S0140-6736(06)69780-8 17126723 (Pubitemid 44794525)
2. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations) Bethesda, MD: National Cancer Institute http://seer.cancer.gov/csr/ 1975-2009-pops09/. 18718969
3. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Estey EH, Am J Hematol 2012 87 89 99 10.1002/ajh.22246 22180162
4. Current findings for recurring mutations in acute myeloid leukemia. Takahashi S, J Hematol Oncol 2011 4 36 10.1186/1756-8722-4-36 21917154
5. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia. Swords R, Freeman C, Giles F, Leukemia 2012 26 2176 2185 10.1038/leu.2012.114 22614177
6. FLT3 inhibition-a moving and evolving target in acute myeloid leukaemia. Leung AY, Man CH, Kwong YL, Leukemia 2012 10.1038/leu.2012.195
7. The role of FLT3 in haematopoietic malignancies. Stirewalt DL, Radich JP, Nat Rev Cancer 2003 3 650 665 10.1038/nrc1169 12951584 (Pubitemid 37328820)
8. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. Gregory TK, Wald D, Chen Y, Vermaat JM, Xiong Y, Tse W, J Hematol Oncol 2009 2 23 10.1186/1756-8722-2-23 19490647
9. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. Takahashi S, J Hematol Oncol 2011 4 13 10.1186/1756-8722-4-13 21453545
10. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H, German-Austrian Acute Myeloid Leukemia Study Group, N Engl J Med 2008 358 1909 1918 10.1056/NEJMoa074306 18450602 (Pubitemid 351620111)
11. Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia. Hofmann M, Große-Hovest L, Nübling T, Pyz E, Bamberg ML, Aulwurm S, Bühring HJ, Schwartz K, Haen SP, Schilbach K, Rammensee HG, Salih HR, Jung G, Leukemia 2012 26 1228 1237 10.1038/leu.2011.372 22289926
12. Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. Zhu X, Ma Y, Liu D, J Hematol Oncol 2010 3 17 10.1186/1756-8722-3-17 20416083
13. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q, Sprankle KG, Patel HK, Levis M, Armstrong RC, James J, Bhagwat SS, Blood 2009 114 2984 2992 10.1182/blood-2009-05-222034 19654408
14. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM, Blood 2003 101 3597 3605 10.1182/blood-2002-07-2307 12531805 (Pubitemid 36857948)
15. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, Kuriyan J, Shah NP, Nature 2012 485 260 263 10.1038/nature11016 22504184
16. Selective FLT3 inhibition of FLT3-ITD(+) acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Moore AS, Faisal A, Gonzalez de Castro D, Bavetsias V, Sun C, Atrash B, Valenti M, de Haven Brandon A, Avery S, Mair D, Mirabella F, Swansbury J, Pearson AD, Workman P, Blagg J, Raynaud FI, Eccles SA, Linardopoulos S, Leukemia 2012 26 1462 1470 10.1038/leu.2012.52 22354205
17. FLT3 as a therapeutic target in AML: still challenging after all these years. Kindler T, Lipka DB, Fischer T, Blood 2010 116 5089 5102 10.1182/blood-2010-04-261867 20705759
18. Bench to Bedside Targeting of FLT3 in Acute Leukemia. Pratz KW, Levis MJ, Curr Drug Targets 2010 11 781 789 10.2174/138945010791320782 20370649
19. Generation and characterization of a highly effective protein substrate for analysis of FLT3 activity. Chen Y, Guo Y, Han J, Ho WT, Li S, Fu X, Zhao Z, J Hematol Oncol 2012 5 39 10.1186/1756-8722-5-39 22800464
20. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Liao AT, Chien MB, Shenoy N, Mendel DB, McMahon G, Cherrington JM, London CA, Blood 2002 100 585 593 10.1182/blood-2001-12-0350 12091352 (Pubitemid 34761123)
21. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, Fukuda JY, Chu JY, Nematalla A, Wang X, Chen H, Sistla A, Luu TC, Tang F, Wei J, Tang C, J Med Chem 2003 46 1116 1119 10.1021/jm0204183 12646019 (Pubitemid 36428215)
22. FLT3 mutations in acute myeloid leukemia cell lines. Quentmeier H, Reinhardt J, Zaborski M, Drexler HG, Leukemia 2003 17 120 124 10.1038/sj.leu.2402740 12529668 (Pubitemid 36175896)
23. The Expression of CD30 in Anaplastic Large Cell Lymphoma Is Regulated by Nucleophosmin-Anaplastic Lymphoma Kinase-Mediated JunB Level in a Cell Type-Specific Manner. Hsu FY, Johnston PB, Burke KA, Zhao Y, Cancer Res 2006 66 9002 9008 10.1158/0008-5472.CAN-05-4101 16982741 (Pubitemid 44521118)
24. JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines. Zhao W, Du Y, Ho WT, Fu X, Zhao ZJ, Experimental Hematology & Oncology 2012 1 15 10.1186/2162-3619-1-15 23242571
25. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. Li Z, Xu M, Xing S, Ho WT, Ishii T, Li Q, Fu X, Zhao ZJ, J Biol Chem 2007 282 3428 3432 17178722 (Pubitemid 47084420)
26. Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity. Li Z, Xing S, Wang S, Ho WT, Zhao ZJ, Exp Hematol 2007 35 1624 1632 10.1016/j.exphem.2007.07.003 17764811 (Pubitemid 47633769)